177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Metastatic Castration-resistant Prostate Cancer Clinical Trial

Official title:

A Phase I/II Study of 177Lu-HTK03170 in Metastatic, Castration-Resistant Prostate Cancer Subjects With Prostate-specific Membrane Antigen-positive Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05570994
• Other study ID #: H22-02395
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 1, 2024
• Est. completion date: May 1, 2027

Study information

• Verified date: July 2023
• Source: British Columbia Cancer Agency
• Contact: Research Manager
• Phone: 604-877-6000
• Email: MITclinicaltrials[@]bccancer.bc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant prostate cancer, (mCRPC). Subjects will receive treatment which will be escalated between cycles and personalized based on dosimetry calculations and imaging. In addition, antitumour activity will be measured by radiographic response, and further assessments of the treatment will be measured by CT imaging, ctDNA/ctRNA, PSA, PSMA PET/CT, and quality of life questionnaires. Subjects will be followed for 2 years or until they have progression and are switched to another systemic treatment.

Description:

Overall, up to 50 subjects will be enrolled to receive an injected activity (IA) of 177Lu-HTK03170. The IA's will be escalated based on personalized dosimetry at subsequent treatments (up to 5 cycles total).

Screening Phase: Subjects will be screened against the inclusion and exclusion criteria. A PSMA PET/CT scan using 68Ga-HTK03149 will be used to confirm PSMA positive disease. Those with confirmed PSMA positive disease with continue to one of the two Treatment Phases. Subjects will be informed which Phase they will be enrolled in.

Subjects will undergo a physical exam, complete a medical history questionnaire, a quality of life questionnaire, blood work, and a diagnostic CT.

Treatment summary per Phase:

The first 3 subjects will receive an initial Initial Acitivity (IA) of 1.1 GBq of 177Lu HTK03170, for the first cycle of treatment, assuming no toxicities occur requiring dose modification. Dosimetry will be performed to obtain absorbed organ dose and effective dose values. The initial IA used for dosimetry will be escalated to improve image quality, radiation dosimetry estimates, and potential efficacy. IA escalation will only occur on the initial dosimetry IA, with an increase of 30% over the initial IA (used for dosimetry) at each subsequent level (1.65 GBq, 2.5 GBq, 3.7 GBq) in up to 12 participants.

IA escalation will cease when a maximum tolerated injected activity (MTIA) is determined or a recommended safe initial IA has been identified based on an integrated assessment of safety, pharmacokinetics (PK), dosimetry, and preliminary antitumour activity data, if available.

Treatment Phase I: During the treatment phase, subjects will undergo up to 5 cycles of treatment. Each treatment cycle will be followed by dosimetry SPECT/CT scans on day 3 (72 +/- 24 hours) after treatment administration, and day 10 (10 days +/- 72 hours) after treatment administration. Additional dosimetry SPECT/CT scans will be completed during Cycle 1, on the day of treatment, and on day 1 (24 hours after treatment). After Cycle 3, a quality of life questionnaire will be completed again.

Treatment Phase II: During the treatment phase, subjects will be treated with an initial IA of 177Lu-HTK03170 at the MTD as determined during Phase I, or 1625 MBq, whichever is lower. Personalized dosimetry will be calculated for each subject as in Phase 1 so that subsequent treatments will be estimated to remain within the absorbed cumulative dose limits of 28Gy and 35Gy for kidneys and salivary glands, respectively, adjusted iteratively over the 3 remaining treatment cycles separated by 8 weeks. Each treatment cycle IA will be further adjusted to ensure a single dose exposure of 2Gy or less to the bone marrow, as needed. Fifteen (15) subjects will be enrolled in the first stage. When 6 or more subjects achieve objective radiographic response based on RECIST v1.1 , the study will proceed to the 2nd stage, where additional 17 subjects will be enrolled to continue efficacy evaluation.

Subjects will undergo up to 5 cycles of treatment. Each treatment cycle will be followed by dosimetry SPECT/CT scans on day 1 (18 - 32 hours after treatment administration) and day 3 (64 - 80h after treatment administration). Additional dosimetry SPECT/CT scans will be completed during Cycle 1, on the day of treatment, and on day 10. A repeat After cycle 5 a quality of life questionnaire will be completed again.

Follow up Phase: At the end of treatment or after discontinuation of any cause, subjects will be followed for 2 years to continue data collection for the other objectives. Objective tumour response will be assessed every 4 months by diagnostic CT according to the RECIST 1.1 criteria. A final quality of life questionnaire will be completed again within 28 days after the last treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: May 1, 2027
• Est. primary completion date: March 1, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Each subject must meet all of the following inclusion criteria to be enrolled in the study:

1. Male subjects = 18 years of age

2. Willing and able to provide consent

3. Life expectancy of > 6 months

4. Progression on treatment with abiraterone and/or enzalutamide, or similar next generation ARAT therapy, as determined by the investigator. Subjects who have received docetaxel in the castration-resistant setting are also eligible to participate. Prior treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor is permitted.

5. Pathologically confirmed prostate adenocarcinoma

6. Subjects must have evidence of biochemical or imaging progression. Progression is defined as any one of the following:

1. Prostate-specific antigen progression: two consecutive rising PSA values from a baseline measurement with an interval of = 1 week between measurements. Minimum PSA at screening visit is = 2.0 µg/L.

2. Soft tissue disease progression on chest, abdomen, pelvis CT or magnetic resonance imaging (MRI; RECIST v1.1)

3. Bone progression: = 2 new lesions on bone scan

7. Eastern Cooperative Oncology Group (ECOG) performance score =2

8. Prior orchiectomy, or if on luteinizing hormone releasing hormone (LHRH) agonist/antagonist, then testosterone < 1.7 nmol/L or < 50 ng/dL

9. Adequate organ function:

a) Marrow i) Absolute neutrophil count = 1.5 × 109 /L ii) Platelet count = 100 ×109 /L iii) Hemoglobin = 90 g/L with no transfusions in the past 2 weeks b) Kidney i) Estimated creatinine clearance =40 ml/min according to Cockroft-Gault equation: ((140

• age) × (weight in kg)) / (72 × (serum creatinine)) c) Liver: i) Bilirubin < 1.0 × upper limit of normal (ULN) (or if bilirubin is between 1.5 to 2 × ULN, must have a normal conjugated bilirubin) ii) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 × ULN in the absence of liver metastases, and) = 5.0 × ULN in the presence of liver metastases.

10. Recovery from all previous cancer treatment toxicities to grade = 2 (as per CTCAE 4.03)

11. Able to comply with scheduled visits, treatment plans, laboratory tests, imaging tests, and other procedures required and detailed in the protocol.

12. Must be surgically sterile or use adequate contraception for the duration of the therapy and 6 months after the end of therapy

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria are not to be enrolled in the study.

1. Prior treatment with 225Ac-PSMA-617, 177Lu-PSMA, other radiolabeled therapeutic PSMA-ligands, or radio-immunotherapy

2. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or targeted therapy) within 28 days prior to day of enrollment

3. Radiotherapy to target lesions (measurable disease) = 4 weeks prior to enrolment

4. Known parenchymal brain metastases

5. Active epidural disease (treated epidural disease is permitted)

6. History of risk factors for xerostomia (ie, head and neck radiation, Sjögren's disease) or pre-existing xerostomia Grade =1

7. Other concomitant active invasive cancer (except superficial non-melanomatous, non-metastatic skin cancer or non-invasive superficial transitional cell carcinoma [TCC])

8. Clinically significant cardiac disease including:

1. History of unstable angina pectoris, symptomatic pericarditis, or myocardial infarction within 6 months prior to study entry.

2. History of documented congestive heart failure (New York Heart Association [NYHA] functional classification III-IV) or cardiomyopathy.

9. Major surgery within 4 weeks of starting study treatment.

10. Unmanageable urinary tract obstruction or hydronephrosis

Related Conditions & MeSH terms

• Castrate Resistant Prostate Cancer
• Metastatic Castration-resistant Prostate Cancer
• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• 177Lu HTK03170
Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
• 68Ga-HTK03149
68Ga-HTK03149 PET/CT imaging; intravenous during screening

Locations

Country	Name	City	State
Canada	BC Cancer	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
British Columbia Cancer Agency

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To assess whether circulating tumour DNA/RNA can be used to predict treatment response	Proportion of subjects with recurrence as defined by ctDNA/ctRNA allele frequency change from pre-treatment to on-treatment	Baseline (week 0), Cycle 3 (Day 1), Cycle 5 (Day 1) (cycle duration for Cycle 1-5 = 8 weeks
Other	To assess the dose-response relationship between radiation delivered to tumour lesions and radiographic objective response	Proportion of subjects achieving a PR, or CR, based on RECIST v1.1, at different tumour absorbed dose levels	up to 8 weeks following treatment cycle/s (cycle durations = 8 weeks)
Primary	To measure the radiation dosimetry of 177Lu-HTK03170 in subjects who have PSMA-positive mCRPC (confirmed by PSMA PET/CT) previously treated with ARAT	Phase I: Absorbed doses to organs and tumors per unit of administered activity (Gy/MBq)	Within 8 weeks of treatments per cycle (cycle durations = 8 weeks)
Primary	To determine the MTIA or a recommended safe initial IA of 177Lu-HTK03170 to measure dosimetry and initiate treatment	Phase I: Occurrence of dose limiting toxicity (DLT) per protocol	Within 8 weeks of treatments per cycle (cycle durations = 8 weeks)
Primary	To determine the number of subjects with AEs, Grade 3 or above AEs, drug-related AEs, and SAEs, based on CTCAE v4.03.	Proportion and distribution of adverse events (AE) is done via the analysis of frequencies for treatment emergent Adverse Event and Serious Adverse Event through the monitoring of relevant clinical and laboratory safety parameters.	Within 8 weeks of treatments per cycle (cycle durations = 8 weeks)
Primary	To determine the number of subjects with AEs leading to discontinuation	Proportion of subjects who permanently discontinue 177Lu-HTK03170 due to toxicity or hypersensitivity	up to 8 weeks post treatment cycle up to 14 weeks post cycle
Primary	Determine the number of subjects with markedly abnormal laboratory tests (including ECG) at least once post-injection	Analysis of the number of subjects with abnormal labs or ECG data parameters as determined by lab assessment reports and 12-lead electrocardiogram (ECG) reporting	up to 8 weeks post treatment cycle
Primary	To determine the antitumour effect of 177Lu-HTK03170 therapy measured by radiographic ORR per RECIST v1.1 in subjects who have PSMA-positive mCRPC	Proportion of subjects achieving a PR, or CR, based on RECIST v1.1	up to 24 months subsequent follow up evaluations
Secondary	Overall Response Rate (ORR)	Proportion of subjects achieving a stable disease lasting for at least 6 months based on RECIST v1.1	at least 6 months subsequent follow-up evaluations
Secondary	Percentage of Participants Achieving Prostate-specific Antigen (PSA) Response	Proportion of subjects achieving prostate-specific antigen (PSA) responses defined as a decline of =50% decline from baseline	from date of baseline assessment to at least 4 weeks post treatment cycle Within 8 weeks of treatments per cycle (cycle durations = 8 weeks)
Secondary	Duration of PSA responses	Duration of PSA response was defined as the duration between the date of first document PSA response (i.e. >= 50% decrease in PSA from Baseline) and the earliest date of PSA progression, where date of PSA progression was defined as: 1) Where a decline from baseline was documented, date that a >= 25% increase in PSA and an absolute increase of 2 ng/mL or more from the nadir was documented and confirmed by a second consecutive value obtained at least 4 weeks later.	From date of first documented PSA response till 4 weeks follow up, assessed up to 24 months post end of last cycle
Secondary	Duration of radiographic response	Duration of radiographic response was defined as the duration between the date of first documented Best Overall Response of Complete Response or Partial Response and the date of first documented radiographic progression or death due to any cause	From first documented evidence of CR or PR (the response prior to confirmation) until time of documented disease progression or death due to any cause, whichever comes first, assessed up to 24 months from end of last cycle
Secondary	Progression free survival at 6 months	Proportion of subjects who are progression-free at 6 months as defined by PSA, objective disease, or symptoms. PSA progression, radiographic progression, or clinical progression per PCWG3 criteria will be assessed separately and combined.	From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 6 months
Secondary	Progression-free Survival (PFS)	Time to PSA progression, radiographic progression, or clinical progression per PCWG3 criteria will be assessed separately and combined.	From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 24 months post end of treatment cycle
Secondary	Time to First Symptomatic Skeletal Event (SSE)	Time to first Symptomatic Skeletal Event (SSE) was defined as the time (in months) from the date of randomization to the date of the SSE or death from any cause. The SSE date was the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurred first.	From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 24 months post end of treatment cycle
Secondary	Change From Baseline in the European Quality of Life (EuroQol) - 5 Domain 5 Level Scale (EQ-5D-5L) Utility Score	The EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ VAS records the patient's self-rated health on a vertical visual analogue 0-100 scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The higher the EQ-VAS score, the better the QoL.	Baseline (week 0), Cycle 3 (Day 1), Follow up (Day 84 of last treatment) (cycle duration for Cycle 1-5 = 8 weeks